Vonoprazan
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease, Helicobacter Pylori Infection
Trial Timeline
May 7, 2024 → Sep 19, 2024
NCT ID
NCT06391177About Vonoprazan
Vonoprazan is a phase 1 stage product being developed by Phathom Pharmaceuticals for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06391177. Target conditions include Erosive Esophagitis, Heartburn, Symptomatic Nonerosive Gasroesophageal Reflux Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06660342 | Pre-clinical | Recruiting |
| NCT06391177 | Phase 1 | Completed |
| NCT06106022 | Phase 1 | Completed |
| NCT05343364 | Phase 1 | Completed |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 85 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 80 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |
Other Products from Phathom Pharmaceuticals
PYTEST® 14C-Urea Capsule Breath Test (at Home) + PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)Approved
80
PYTEST® 14C-Urea Breath Test + VOQUEZNA® Triple Pak®Approved
80
Vonoprazan + LansoprazolePhase 3
72
Vonoprazan + Amoxicillin + Clarithromycin + LansoprazolePhase 3
72
Vonoprazan + PlaceboPhase 3
72